Julia A Messina1, Eric Cober2, Sandra S Richter3, Federico Perez4, Robert A Salata5, Robert C Kalayjian6, Richard R Watkins7, Nikole M Scalera8, Yohei Doi9, Keith S Kaye10, Scott Evans11, Robert A Bonomo4, Vance G Fowler1, David van Duin12. 1. 1Division of Infectious Diseases,Duke University,Durham,North Carolina. 2. 3Department of Infectious Diseases,Cleveland Clinic,Cleveland,Ohio. 3. 4Department of Laboratory Medicine,Cleveland Clinic,Cleveland,Ohio. 4. 5Research Service,Louis Stokes Veterans Affairs Medical Center,Cleveland,Ohio. 5. 6Division of Infectious Diseases and HIV Medicine,Department of Medicine,Case Western Reserve University School of Medicine,Cleveland,Ohio. 6. 7Department of Medicine,MetroHealth Medical Center,Cleveland,Ohio. 7. 8Department of Internal Medicine,Northeast Ohio Medical University,Rootstown,Ohio. 8. 10Division of Infectious Diseases,Summa Health System,Akron,Ohio. 9. 11Division of Infectious Diseases,University of Pittsburgh School of Medicine,Pittsburgh,Pennsylvania. 10. 12Division of Infectious Diseases,Detroit Medical Center,Wayne State University,Detroit,Michigan. 11. 13Department of Biostatistics and the Center for Biostatistics in AIDS Research,Harvard School of Public Health,Boston,Massachusetts. 12. 16Division of Infectious Diseases,University of North Carolina,Chapel Hill,North Carolina.
Abstract
BACKGROUND: Various transmission routes contribute to spread of carbapenem-resistant Klebsiella pneumoniae (CRKP) in hospitalized patients. Patients with readmissions during which CRKP is again isolated ("CRKP readmission") potentially contribute to transmission of CRKP. OBJECTIVE: To evaluate CRKP readmissions in the Consortium on Resistance against Carbapenems in K. pneumoniae (CRaCKLe). DESIGN: Cohort study from December 24, 2011, through July 1, 2013. SETTING: Multicenter consortium of acute care hospitals in the Great Lakes region. PATIENTS: All patients who were discharged alive during the study period were included. Each patient was included only once at the time of the first CRKP-positive culture. METHODS: All readmissions within 90 days of discharge from the index hospitalization during which CRKP was again found were analyzed. Risk factors for CRKP readmission were evaluated in multivariable models. RESULTS: Fifty-six (20%) of 287 patients who were discharged alive had a CRKP readmission. History of malignancy was associated with CRKP readmission (adjusted odds ratio [adjusted OR], 3.00 [95% CI, 1.32-6.65], P<.01). During the index hospitalization, 160 patients (56%) received antibiotic treatment against CRKP; the choice of regimen was associated with CRKP readmission (P=.02). Receipt of tigecycline-based therapy (adjusted OR, 5.13 [95% CI, 1.72-17.44], using aminoglycoside-based therapy as a reference in those treated with anti-CRKP antibiotics) was associated with CRKP readmission. CONCLUSION: Hospitalized patients with CRKP-specifically those with a history of malignancy-are at high risk of readmission with recurrent CRKP infection or colonization. Treatment during the index hospitalization with a tigecycline-based regimen increases this risk.
BACKGROUND: Various transmission routes contribute to spread of carbapenem-resistant Klebsiella pneumoniae (CRKP) in hospitalized patients. Patients with readmissions during which CRKP is again isolated ("CRKP readmission") potentially contribute to transmission of CRKP. OBJECTIVE: To evaluate CRKP readmissions in the Consortium on Resistance against Carbapenems in K. pneumoniae (CRaCKLe). DESIGN: Cohort study from December 24, 2011, through July 1, 2013. SETTING: Multicenter consortium of acute care hospitals in the Great Lakes region. PATIENTS: All patients who were discharged alive during the study period were included. Each patient was included only once at the time of the first CRKP-positive culture. METHODS: All readmissions within 90 days of discharge from the index hospitalization during which CRKP was again found were analyzed. Risk factors for CRKP readmission were evaluated in multivariable models. RESULTS: Fifty-six (20%) of 287 patients who were discharged alive had a CRKP readmission. History of malignancy was associated with CRKP readmission (adjusted odds ratio [adjusted OR], 3.00 [95% CI, 1.32-6.65], P<.01). During the index hospitalization, 160 patients (56%) received antibiotic treatment against CRKP; the choice of regimen was associated with CRKP readmission (P=.02). Receipt of tigecycline-based therapy (adjusted OR, 5.13 [95% CI, 1.72-17.44], using aminoglycoside-based therapy as a reference in those treated with anti-CRKP antibiotics) was associated with CRKP readmission. CONCLUSION: Hospitalized patients with CRKP-specifically those with a history of malignancy-are at high risk of readmission with recurrent CRKP infection or colonization. Treatment during the index hospitalization with a tigecycline-based regimen increases this risk.
Authors: David van Duin; Eric Cober; Sandra S Richter; Federico Perez; Robert C Kalayjian; Robert A Salata; Scott Evans; Vance G Fowler; Keith S Kaye; Robert A Bonomo Journal: J Antimicrob Chemother Date: 2014-12-09 Impact factor: 5.790
Authors: Sandeep Kochar; Timothy Sheard; Roopali Sharma; Alan Hui; Elaine Tolentino; George Allen; David Landman; Simona Bratu; Michael Augenbraun; John Quale Journal: Infect Control Hosp Epidemiol Date: 2009-05 Impact factor: 3.254
Authors: Pratik Bhagunde; Francheska Colon-Gonzalez; Yang Liu; Jin Wu; Shiyao Sherrie Xu; Graigory Garrett; Patricia Jumes; Kenneth Lasseter; Thomas Marbury; Matthew L Rizk; Mallika Lala; Elizabeth G Rhee; Joan R Butterton; Keith Boundy Journal: Br J Clin Pharmacol Date: 2020-01-23 Impact factor: 4.335
Authors: Yohei Doi; Robert A Bonomo; David C Hooper; Keith S Kaye; James R Johnson; Cornelius J Clancy; Joshua T Thaden; Martin E Stryjewski; David van Duin Journal: Clin Infect Dis Date: 2017-03-15 Impact factor: 9.079
Authors: Renee Ackley; Danya Roshdy; Jacqueline Meredith; Sarah Minor; William E Anderson; Gerald A Capraro; Christopher Polk Journal: Antimicrob Agents Chemother Date: 2020-04-21 Impact factor: 5.191
Authors: David van Duin; Judith J Lok; Michelle Earley; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Vance G Fowler; David L Paterson; Robert A Bonomo; Scott Evans Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079
Authors: Heather Henderson; Courtney L Luterbach; Eric Cober; Sandra S Richter; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Scott Evans; Vance G Fowler; Robert A Bonomo; Anthony Harris; Sonia Napravnik; David Van Duin Journal: Clin Infect Dis Date: 2020-04-15 Impact factor: 9.079